RPRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RP

Mkt Cap

$27.15B

Volume

5.05M

Next Earnings

November 4th

Loading chart

RP

RPRXRoyalty Pharma plc Class A Ordinary Shares

RPRX

Pay with—

Available Balance0.00

RP

Mkt Cap

$26.55B

Volume

5.05M

Next Earnings

November 4th

Chart Financials Earnings News About Dividends Insider Filings

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.Zacks Investment Research · Oct 13, 2026

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates AgainRoyalty Pharma (RPRX) has demonstrated a consistent track record of beating earnings estimates, with an average surprise of 5.25% over the past two quarters. The company's positive Earnings ESP of +0.21% combined with its Zacks Rank #3 (Hold) suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time.Zacks Investment Research · Oct 8, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.The Motley Fool · Oct 1, 2026

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The article compares Amgen, an established biotech giant with $36.7B in revenue and strong profitability, against Revolution Medicines, a clinical-stage oncology company with no approved products but a breakthrough cancer therapy (Daraxonrasib) that showed 50%+ reduction in death risk for metastatic pancreatic cancer. The author recommends Revolution Medicines for long-term investors willing to accept biotech risk, citing the paradigm-shifting potential of its RAS-targeted cancer pipeline, despite current losses and competitive pressures.The Motley Fool · Sep 11, 2026

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenRoyalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a). Despite the setback, Royalty Pharma expects to recoup its total $500 million investment and earn a modest positive return due to its protective deal structure that prioritized stable Spinraza royalties. The company reiterates its 2030 Portfolio Receipts target of $4.7 billion or more.GlobeNewswire Inc. · Sep 4, 2026

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationRoyalty Pharma announced the launch of the Royalty Pharma Translational Prize, a $1 million annual award recognizing exceptional achievements in translational medicine that bridge fundamental discovery and drug development. The prize will be administered independently and presented annually starting in spring 2027 at the Accelerating Bio-Innovation conference, chaired by Nobel Laureate Sir Gregory Winter.GlobeNewswire Inc. · Apr 21, 2026

Royalty Pharma Declares Second Quarter 2026 DividendRoyalty Pharma plc (NASDAQ: RPRX) announced a dividend of $0.235 per Class A ordinary share for Q2 2026, payable on June 10, 2026, to shareholders of record as of May 15, 2026. The company continues to generate returns from its portfolio of royalties on over 35 commercial pharmaceutical products.Benzinga · Apr 17, 2026

Zymeworks Appoints Kristin Stafford as Chief Financial OfficerZymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executing strategic priorities.GlobeNewswire Inc. · Apr 1, 2026

Vera Therapeutics Appoints Christopher Hite to Board of DirectorsVera Therapeutics announced the appointment of Christopher Hite, Executive Vice President and Vice Chairman of Royalty Pharma, to its Board of Directors. Hite brings over 25 years of biopharmaceutical industry experience and will serve as an independent board member as the company prepares for the potential launch of atacicept, its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy treatment.GlobeNewswire Inc. · Mar 5, 2026

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global PlatformRoyalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026, based in Hong Kong. The move capitalizes on the rapidly growing Asian biotech market, where Chinese medicine out-licensing reached over $130 billion in transaction value in 2025, up from $14 billion in 2021. Sun, formerly Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, will lead efforts to establish the royalty market in Asia similar to Royalty Pharma's foundational role in the Western market.GlobeNewswire Inc. · Mar 2, 2026

to start trading

RP

RPRXRoyalty Pharma plc Class A Ordinary Shares

RPRX

Pay with—

Available Balance0.00

Your PositionYou don't own any RPRX yet.

Related Tickers

Earnings

Dividends

Last · Aug 14Quarterly

Amount$0.24

Yield1.52%

Annual$0.92